Advanced Therapy Medicinal Products
A.Y. 2025/2026
Learning objectives
The objective of the course is to provide the students with the skills to understand the strategies for the design of medicine for advanced therapies, such as gene therapy and cell therapy. In addition, the course will provide the basis to understand the evolution of anti-infective drugs.
Expected learning outcomes
At the end of the course, students will have the knowledge to design and optimize medicines for advanced therapies. In addition, students will have the skills to present clearly and with a proper language, and to correctly refer to information sources.
Lesson period: First semester
Assessment methods: Esame
Assessment result: voto verbalizzato in trentesimi
Single course
This course cannot be attended as a single course. Please check our list of single courses to find the ones available for enrolment.
Course syllabus and organization
Single session
Responsible
Lesson period
First semester
Course syllabus
Introduction to advanced therapies: gene therapy, cell therapy and stem cells, tissue therapy, CRISPR and genomic editing, CAR-T and immunotherapy, RNA therapies. Definition, ethical and regulatory aspects for the development of advanced therapy medical products.
Introduction to advanced therapies in the field of infectious diseases: causes of the limited availability of drugs against acute infections and implications of pathogenic targets vs. host targets.
Advanced therapy medical products approved in therapy.
Design and optimization strategies for innovative drugs for advanced therapies in the preclinical/clinical development.
New pharmaceutical technologies for anti-infectives: RNA drugs for chronic viral hepatitis, gene/epigenetic editing for HIV and hepatitis B, and the development and use of monoclonal antibodies for the treatment of infections.
Introduction to advanced therapies in the field of infectious diseases: causes of the limited availability of drugs against acute infections and implications of pathogenic targets vs. host targets.
Advanced therapy medical products approved in therapy.
Design and optimization strategies for innovative drugs for advanced therapies in the preclinical/clinical development.
New pharmaceutical technologies for anti-infectives: RNA drugs for chronic viral hepatitis, gene/epigenetic editing for HIV and hepatitis B, and the development and use of monoclonal antibodies for the treatment of infections.
Prerequisites for admission
The student must know the principles underlying general pharmacology, biochemistry, physiology and pathology.
Teaching methods
Frontal lessons accompanied by thematic insights offered to students.
Teaching Resources
RNA Therapeutics in Human Diseases di Saw, Phei Er. author.; Song, Erwei.
Biotechnologies for gene therapy: RNA, CRISPR, nanobots, and preclinical applications di Yoder, Kristine E., editor.; Yun, Yang, editor.
Biotechnologies for gene therapy: RNA, CRISPR, nanobots, and preclinical applications di Yoder, Kristine E., editor.; Yun, Yang, editor.
Assessment methods and Criteria
The exam consists of an oral test during which the level of knowledge of the concepts described during the course will be assessed and the candidate's critical ability will be assessed regarding the aspects to be considered in the design of advanced therapy medical products. The evaluation is expressed in thirtieths.
BIO/14 - PHARMACOLOGY - University credits: 7
BIO/19 - MICROBIOLOGY - University credits: 2
BIO/19 - MICROBIOLOGY - University credits: 2
Lessons: 72 hours
Professors:
Manganaro Lara, Ossoli Alice Federica
Professor(s)